{
  "emaEpar": [],
  "fdaDrugLabel": [],
  "id": "Sipuleucel-T",
  "nciThesaurus": {
    "casRegistry": "917381-47-6",
    "chebiId": "",
    "chemicalFormula": "",
    "definition": "A cell-based vaccine composed of autologous antigen-presenting peripheral blood mononuclear cells (enriched for a dendritic cell fraction) that have been exposed to a recombinant protein consisting of granulocyte-macrophage colony-stimulating factor (GM-CSF) fused to prostatic-acid phosphatase (PAP), a protein expressed by prostate cancer cells.  Upon administration, the vaccine may stimulate an antitumor T-cell response against tumor cells expressing PAP. (NCI05)",
    "fdaUniiCode": "8Q622VDR18",
    "identifier": "C1985",
    "preferredName": "Sipuleucel-T",
    "semanticType": "Cell",
    "subclassOf": [
      "C129826",
      "C1987"
    ],
    "synonyms": [
      "APC8015",
      "APC8015 Vaccine",
      "PA2024 (PAP/GM-CSF)-Loaded Dendritic Cell Vaccine",
      "Provenge",
      "SIPULEUCEL-T",
      "SipT",
      "Sipuleucel-T",
      "sipuleucel-T"
    ]
  }
}